A US appeals court has ruled that Regeneron and Sanofi’s Praluent can stay on the market while they appeal a patent case from rival Amgen that blocked them from selling it. Last month ...

Those shares have been surging, up 24% since 29 th November, when the company disclosed that Amgen, as well as Sanofi and a Johnson & Johnson unit, were in preliminary talks surrounding an ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

The U.S. Patent Office has published updated examination guidelines regarding the enablement requirement in view of the ...

Amgen (AMGN) stock slid more than 4.5% at the start of Wednesday trading after the pharmaceutical giant reported the results ...

Recombinant Dna Technology Market Set To Witness Significant Growth By 2024-2031: Sanofi , Pfizer, Inc., Amgen, Inc. Recombinant Dna technology market is expected to reach USD 327.63 Bn by 2031, ...

ASCO: With first-in-class win, Sanofi's Sarclisa looks to step out of ... There’s also a combination of Sarclisa with Amgen’s Kyprolis, lenalidomide and dexamethasone (KRd).

Amgen (AMGN) shares were down 5% Wednesday, the day after the company reported Phase 3 results for its drugs rocatinlimab and ...

Bank of America Securities analyst Graham Parry maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target ...

Amgen shares fell 4.5% after the biotech revealed disappointing study results for two closely watched drug candidates. The company, in a call with analysts and investors, reported positiv ...

IMTOZ trial findings and subsequent approval of Isa-VRd regimen for transplant-ineligible myeloma suggested the combo as a ...